|Bid||95.6800 x 1100|
|Ask||95.8500 x 800|
|Day's Range||92.64 - 97.62|
|52 Week Range||75.81 - 106.74|
|Beta (3Y Monthly)||1.66|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 20, 2019 - Feb 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||121.67|
Today, Neurocrine Biosciences (NBIX) is trading at $67.91, a ~20.83% fall from its closing price of $85.76 on December 11. Neurocrine stock has hit its 52-week low of $64.72. Neurocrine stock was trading at $103.0 at the close of market on November 12, and it reached $85.69 on December 11, representing a ~17% fall in the month.
Jean-Jacques Bienaimé has been the CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) since 2005. This report will, first, examine the CEO compensation levels in comparison to CEO compensation at other big Read More...
The 700+ hedge funds and money managers tracked by Insider Monkey have already compiled and submitted their 13F filings for the second quarter, which unveil their equity positions as of September 30. We went through these filings, fixed typos and other more significant errors and identified the changes in hedge fund positions. Our extensive review […]
NEW YORK, Dec. 07, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Shire's (SHPG) pending acquisition by Takeda Pharmaceuticals for $62 billion gets approval from shareholders of both the companies.
SAN RAFAEL, Calif. , Dec. 3, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced the promotion of Amy Wireman to Group Vice President, Human Resources. Ms. Wireman's promotion ...
SAN RAFAEL, Calif. , Dec. 3, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will participate in Citi's 13th Annual Biotech Conference on December 5 in ...
BioMarin Pharmaceutical’s (BMRN) Vimizim’s net revenues over the first nine months of this year amounted to $368.0 million compared to $299.3 million in the same period the prior year, reflecting ~23% YoY growth. In the third quarter, BioMarin Pharmaceutical’s Vimizim generated revenues of $123.3 million, representing ~37% YoY growth. Kuvan’s net revenues over the first nine months of this year amounted to $321.4 million compared to $300.1 million in the same period the prior year, reflecting ~7% YoY growth.
Bayer AG will cut 12,000 jobs globally and shut a recently constructed hemophilia drug-making facility in Germany, consolidating manufacturing of its blood-clotting drugs in Berkeley. Bayer has no plans to recall people to the roughly 400 manufacturing-related jobs it has cut over the past year in Berkeley, the only unionized biotech workforce in the United States.
BioMarin Pharmaceutical’s (BMRN) net revenues over the first nine months of this year amounted to $1.1 billion compared to $955.3 million in the same period the prior year, a ~19% YoY increase. BioMarin Pharmaceutical reported net revenues of $391.7 million in the third quarter, which reflected ~17% YoY growth.
BioMarin Pharmaceutical’s net income and EPS for the first nine months of this year amounted to -$73.6 million and -$0.42, respectively, compared to -$65.7 million and -$0.38 in the same period the prior year.
Bayer announced Thursday it will cut 12,000 jobs amid a strategic overhaul to focus on its pharmaceuticals, consumer health and crop science businesses.
The U.S. Food and Drug Administration approved on Wednesday Catalyst Pharmaceuticals Inc's drug to treat a rare autoimmune disease. The drug, Firdapse, becomes the first approved treatment for Lambert-Eaton ...
In November, of the total 21 analysts covering Tesaro (TSRO) stock, 13 have given it “buy” or higher ratings, and eight have given it “hold” ratings.
For 2018 and 2019, Tesaro (TSRO) is expected to generate revenues of $260.77 million and $349.89 million, respectively, compared to $223.33 million in 2017.
Sarepta's (SRPT) key product, Exondys 51, continues to perform well. Its lead pipeline candidate, golodirsen, is also making good progress. The company is also developing gene therapies.
BioMarin Pharmaceutical Inc (BMRN.O) is turning to the theatre to establish its name with haemophilia patients, long before its experimental cure for the bleeding disorder could reach the market. Earlier this month, BioMarin hosted 25 teenagers and their chaperones for an all-expenses paid trip to New York City, where they performed a Broadway-style musical based on their own experiences with bleeding disorders. Well beyond a feel-good philanthropic effort, BioMarin’s business strategy here is to build a long-term relationship with haemophilia patients who it wants to one day use its gene therapy.
BioMarin Pharmaceutical Inc is turning to the theater to establish its name with hemophilia patients, long before its experimental cure for the bleeding disorder could reach the market. Earlier this month, BioMarin hosted 25 teenagers and their chaperones for an all-expenses paid trip to New York City, where they performed a Broadway-style musical based on their own experiences with bleeding disorders. Well beyond a feel-good philanthropic effort, BioMarin’s business strategy here is to build a long-term relationship with hemophilia patients who it wants to one day use its gene therapy.
In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.
BioMarin's clinical trial of a gene therapy for hemophilia is providing hope to patients with the disease. It is an experimental treatment that uses a virus to deliver a healthy copy of a gene to make up for one that causes excessive bleeding.